These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 29660782)

  • 21. Efficacy and safety of luseogliflozin added to insulin therapy in Japanese patients with type 2 diabetes: a multicenter, 52-week, clinical study with a 16-week, double-blind period and a 36-week, open-label period.
    Seino Y; Sasaki T; Fukatsu A; Imazeki H; Ochiai H; Sakai S
    Curr Med Res Opin; 2018 Jun; 34(6):981-994. PubMed ID: 29448833
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effects of intermittent use of the SGLT-2 inhibitor, dapagliflozin, in overweight patients with type 2 diabetes in Japan: a randomized, crossover, controlled clinical trial.
    Kato K; Suzuki K; Aoki C; Sagara M; Niitani T; Wakamatsu S; Yanagi K; Aso Y
    Expert Opin Pharmacother; 2017 Jun; 18(8):743-751. PubMed ID: 28426260
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Luseogliflozin and other sodium-glucose cotransporter 2 inhibitors: no enemy but time?
    Pafili K; Papanas N
    Expert Opin Pharmacother; 2015 Mar; 16(4):453-6. PubMed ID: 25605060
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Luseogliflozin, A Sodium Glucose Co-transporter 2 Inhibitor, Alleviates Hepatic Impairment in Japanese Patients with Type 2 Diabetes.
    Kusunoki M; Natsume Y; Sato D; Tsutsui H; Miyata T; Tsutsumi K; Suga T; Oshida Y
    Drug Res (Stuttg); 2016 Nov; 66(11):603-606. PubMed ID: 27626603
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium-glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes.
    Yabe D; Shiki K; Suzaki K; Meinicke T; Kotobuki Y; Nishida K; Clark D; Yasui A; Seino Y
    BMJ Open; 2021 Apr; 11(4):e045844. PubMed ID: 33827843
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Substantial Effects of Luseogliflozin Revealed by Analyzing Responses to Postprandial Hyperglycemia: Post Hoc Subanalyses of a Randomized Controlled Study.
    Samukawa Y; Omiya H; Watase H; Nozaki K; Sakai S; Nishimura R
    Adv Ther; 2016 Jul; 33(7):1215-30. PubMed ID: 27255763
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Switching from low-dose thiazide diuretics to sodium-glucose cotransporter 2 inhibitor improves various metabolic parameters without affecting blood pressure in patients with type 2 diabetes and hypertension.
    Kimura T; Sanada J; Shimoda M; Hirukawa H; Fushimi Y; Nishioka M; Kinoshita T; Okauchi S; Obata A; Kohara K; Tatsumi F; Kamei S; Nakanishi S; Mune T; Kaku K; Kaneto H
    J Diabetes Investig; 2018 Jul; 9(4):875-881. PubMed ID: 29110406
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes in urinary glucose concentration and body weight in patients treated with the selective SGLT2 inhibitor luseogliflozin.
    Jinnouchi H; Yoshida A; Tsuyuno H; Iwamoto K; Sugiyama S; Hieshima K; Kajiwara K; Kurinami N; Suzuki T; Jinnouchi K; Jinnouchi T
    Diabetes Res Clin Pract; 2021 Dec; 182():108916. PubMed ID: 34119556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.
    Bolinder J; Ljunggren Ö; Johansson L; Wilding J; Langkilde AM; Sjöström CD; Sugg J; Parikh S
    Diabetes Obes Metab; 2014 Feb; 16(2):159-69. PubMed ID: 23906445
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ipragliflozin effectively reduced visceral fat in Japanese patients with type 2 diabetes under adequate diet therapy.
    Yamamoto C; Miyoshi H; Ono K; Sugawara H; Kameda R; Ichiyama M; Yamamoto K; Nomoto H; Nakamura A; Atsumi T
    Endocr J; 2016 Jun; 63(6):589-96. PubMed ID: 27052123
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of luseogliflozin on bone microarchitecture in older patients with type 2 diabetes: study protocol for a randomized controlled pilot trial using second-generation, high-resolution, peripheral quantitative computed tomography (HR-pQCT).
    Haraguchi A; Shigeno R; Horie I; Morimoto S; Ito A; Chiba K; Kawazoe Y; Tashiro S; Miyamoto J; Sato S; Yamamoto H; Osaki M; Kawakami A; Abiru N
    Trials; 2020 May; 21(1):379. PubMed ID: 32370806
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of ipragliflozin and metformin for visceral fat reduction in patients with type 2 diabetes receiving treatment with dipeptidyl peptidase-4 inhibitors in Japan: a study protocol for a prospective, multicentre, blinded-endpoint phase IV randomised controlled trial (PRIME-V study).
    Koshizaka M; Ishikawa K; Ishikawa T; Kobayashi K; Takemoto M; Horikoshi T; Shimofusa R; Takahashi S; Nagashima K; Sato Y; Tatsuno I; Terano T; Hashimoto N; Kuribayashi N; Uchida D; Yokote K;
    BMJ Open; 2017 May; 7(5):e015766. PubMed ID: 28490565
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics and Pharmacodynamics of Luseogliflozin, a Selective SGLT2 Inhibitor, in Japanese Patients With Type 2 Diabetes With Mild to Severe Renal Impairment.
    Samukawa Y; Haneda M; Seino Y; Sasaki T; Fukatsu A; Kubo Y; Sato Y; Sakai S
    Clin Pharmacol Drug Dev; 2018 Nov; 7(8):820-828. PubMed ID: 29693800
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of SGLT2 inhibitors on body composition, fluid status and renin-angiotensin-aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy.
    Schork A; Saynisch J; Vosseler A; Jaghutriz BA; Heyne N; Peter A; Häring HU; Stefan N; Fritsche A; Artunc F
    Cardiovasc Diabetol; 2019 Apr; 18(1):46. PubMed ID: 30953516
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sodium glucose co-transporter 2 inhibitor luseogliflozin in the management of type 2 diabetes: a drug safety evaluation.
    Yabe D; Hamamoto Y; Seino Y; Kuwata H; Kurose T; Seino Y
    Expert Opin Drug Saf; 2017 Oct; 16(10):1211-1218. PubMed ID: 28741382
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of sodium-glucose transporter 2 inhibitors on sarcopenia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
    Zhang S; Qi Z; Wang Y; Song D; Zhu D
    Front Endocrinol (Lausanne); 2023; 14():1203666. PubMed ID: 37465122
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study.
    Hiruma S; Shigiyama F; Hisatake S; Mizumura S; Shiraga N; Hori M; Ikeda T; Hirose T; Kumashiro N
    Cardiovasc Diabetol; 2021 Feb; 20(1):32. PubMed ID: 33530982
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Luseogliflozin: first global approval.
    Markham A; Elkinson S
    Drugs; 2014 Jun; 74(8):945-50. PubMed ID: 24848756
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of luseogliflozin on the secretion of islet hormones and incretins in patients with type 2 diabetes.
    Bando S; Ichikawa R; Taguchi T; Fujimoto K; Motomiya T; Taguchi M; Takano K; Shichiri M; Miyatsuka T
    Endocr J; 2022 Jun; 69(6):681-687. PubMed ID: 35067495
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of luseogliflozin on arterial properties in patients with type 2 diabetes mellitus: The multicenter, exploratory LUSCAR study.
    Kario K; Okada K; Murata M; Suzuki D; Yamagiwa K; Abe Y; Usui I; Tsuchiya N; Iwashita C; Harada N; Okawara Y; Ishibashi S; Hoshide S
    J Clin Hypertens (Greenwich); 2020 Sep; 22(9):1585-1593. PubMed ID: 32810338
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.